自動視野分析儀市場機會、成長動力、產業趨勢分析與 2025 - 2034 年預測

2024 年全球自動視野分析儀市場規模達到 2.314 億美元，預計 2025 年至 2034 年期間的複合年成長率為 5.8%。 這一成長軌跡受到技術進步、眼科疾病發病率上升以及對早期診斷在保護視力方面的關鍵作用的認知不斷提高的推動。自動視野分析儀已成為現代眼科中不可或缺的設備，可以非常準確地幫助檢測和監測視力障礙。

技術創新，特別是人工智慧和機器學習的融合，顯著提高了自動視野分析儀的效率和精確度。這些進步使得診斷結果更快、更準確，滿足了醫院和專科眼科診所對尖端診斷工具日益成長的需求。此外，使用者友善的介面和增強的測試能力推動了不同臨床環境中的廣泛應用，鞏固了這些設備在現代眼科護理中的作用。

市場依產品類型分為靜態分析儀和動態分析儀。靜態分析儀將穩定成長，預計複合年成長率為 5.5%，到 2034 年將達到 2.761資料美元。它們的可靠性和易用性使其成為臨床診斷和研究應用的首選。青光眼是全世界視力喪失的主要原因，尤其是在老年人口中，其盛行率的不斷上升進一步促進了該領域的成長。

根據應用，市場涵蓋青光眼、老年黃斑部病變 (AMD)、神經系統疾病和其他用途。預計青光眼市場將以 6.3% 的強勁複合年成長率成長，到 2034 年將產生 1.752 億美元的產值。自動視野分析儀擅長檢測和監測青光眼進展，提供早期介入的機會並降低不可逆視力喪失的風險。

美國自動視野分析儀市值在 2024 年達到 7,690 萬美元，預計到 2034 年將以 4.8% 的複合年成長率成長。老齡化人口對這些疾病的敏感度更高，這也增加了定期眼科檢查和先進診斷技術的需求。持續的創新，尤其是人工智慧和機器學習的應用，不斷提高診斷的準確性和效率，推動了這些設備在美國醫療保健領域的應用。

目錄

第 1 章：方法論與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 青光眼和其他眼部疾病的盛行率上升
    • 更重視早期診斷
    • 在神經系統評估的應用
    • 門診眼科護理需求不斷成長
  • 產業陷阱與挑戰
    • 設備成本高
• 成長潛力分析
• 監管格局
• 報銷場景
• 技術格局
• 差距分析
• 波特的分析
• PESTEL 分析
• 未來市場趨勢

第4章：競爭格局

• 介紹
• 公司矩陣分析
• 公司市佔率分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第 5 章：市場估計與預測：按產品類型，2021 年至 2034 年

• 主要趨勢
• 靜止的
• 動能

第 6 章：市場估計與預測：按應用，2021 年至 2034 年

• 主要趨勢
• 青光眼
• 老年黃斑部病變（AMD）
• 神經系統疾病
• 其他應用

第 7 章：市場估計與預測：依最終用途，2021 年至 2034 年

• 主要趨勢
• 醫院
• 眼科診所
• 其他最終用戶

第 8 章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第9章：公司簡介

• Canon
• ESSILOR INSTRUMENTS
• HAAG-STREIT GROUP
• HEIDELBERG ENGINEERING
• Konan Medical
• Kowa
• MEDA
• Metrovision
• OCULUS
• Optopol
• Reichert AMETEK
• Rexxam
• TOPCON Healthcare
• Zeiss

The Global Automated Visual Field Analyzer Market reached USD 231.4 million in 2024 and is projected to grow at a CAGR of 5.8% between 2025 and 2034. This growth trajectory is fueled by technological advancements, a rising incidence of ophthalmic disorders, and increasing awareness of the critical role early diagnosis plays in preserving vision. Automated visual field analyzers have become indispensable in modern ophthalmology, aiding in the detection and monitoring of vision impairments with remarkable accuracy.

Technological innovations, particularly the integration of artificial intelligence and machine learning, have significantly enhanced the efficiency and precision of automated visual field analyzers. These advancements enable faster, more accurate results, meeting the growing demand for cutting-edge diagnostic tools in hospitals and specialized eye clinics. Additionally, user-friendly interfaces and enhanced testing capabilities have driven widespread adoption across diverse clinical environments, solidifying the role of these devices in modern eye care.

The market is segmented by product type into static and kinetic analyzers. Static analyzers are set to witness steady growth, with a projected CAGR of 5.5%, reaching USD 276.1 million by 2034. These devices evaluate fixed points within a patient's visual field, offering highly accurate and reproducible data crucial for the early detection of visual impairments. Their reliability and ease of use make them a top choice for clinical diagnostics and research applications. The segment growth is further bolstered by the increasing prevalence of glaucoma, a leading cause of vision loss worldwide, particularly among aging populations.

By application, the market encompasses glaucoma, age-related macular degeneration (AMD), neurological disorders, and other uses. The glaucoma segment is expected to grow at a robust CAGR of 6.3%, generating USD 175.2 million by 2034. Rising cases of glaucoma, driven by risk factors such as diabetes and hypertension, underscore the need for advanced diagnostic tools. Automated visual field analyzers excel in detecting and monitoring glaucoma progression, providing opportunities for early intervention and reducing the risk of irreversible vision loss.

The U.S. market for automated visual field analyzers, valued at USD 76.9 million in 2024, is anticipated to grow at a CAGR of 4.8% through 2034. This growth is driven by the increasing prevalence of vision-related disorders, including glaucoma, AMD, and diabetic retinopathy. An aging population with a higher susceptibility to these conditions amplifies the need for regular eye examinations and advanced diagnostic technologies. Ongoing innovation, particularly the adoption of AI and ML, continues to enhance diagnostic accuracy and efficiency, fueling the adoption of these devices across the U.S. healthcare landscape.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of glaucoma and other eye disorders
    • 3.2.1.2 Increased focus on early diagnosis
    • 3.2.1.3 Adoption in neurological assessments
    • 3.2.1.4 Rising demand for outpatient eye care
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of devices
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Reimbursement scenario
• 3.6 Technology landscape
• 3.7 Gap analysis
• 3.8 Porter's analysis
• 3.9 PESTEL analysis
• 3.10 Future market trends

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Static
• 5.3 Kinetic

Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Glaucoma
• 6.3 Age-related macular degeneration (AMD)
• 6.4 Neurological disorders
• 6.5 Other applications

Chapter 7 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Ophthalmic clinics
• 7.4 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Canon
• 9.2 ESSILOR INSTRUMENTS
• 9.3 HAAG-STREIT GROUP
• 9.4 HEIDELBERG ENGINEERING
• 9.5 Konan Medical
• 9.6 Kowa
• 9.7 MEDA
• 9.8 Metrovision
• 9.9 OCULUS
• 9.10 Optopol
• 9.11 Reichert AMETEK
• 9.12 Rexxam
• 9.13 TOPCON Healthcare
• 9.14 Zeiss